Tetra commences PoC clinical trial of PPP003v for companion dogs
Category: #health  By Saipriya Iyer  Date: 2020-02-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Tetra commences PoC clinical trial of PPP003v for companion dogs

Tetra Bio-Pharma Inc., a Canadian pharmaceutical firm that specializes in cannabinoid-derived drug therapy, has recently initiated a clinical study of synthetic cannabinoid therapy (PPP003v) for ophthalmic eye pain in veterinary setting.

Reportedly, Tetra joined forces with a veterinary ophthalmology team to commence the recruitment process for in-life phase proof of concept clinical study in companion dogs that suffer from indolent corneal ulcers. On February 21, the research team successfully treated their first dog. 

The clinical trial, which is approved by Health Canada, is developed to assess the tolerability, potential efficacy, and safety of PPP003v to ameliorate symptoms of ophthalmic eye disease in canines. For the record, indolent corneal ulcers are frequently observed in certain breeds of dogs. This type of ulcer comes as the most usual type of eye disorder in veterinarians and if left untreated, could cause severe inflammation, pain, vision loss, and scarring. 

According to reports, PPP003v is Tetra’s exclusive veterinary ocular solution for treating inflammation and ocular pain in pet animals. It was patented and developed by the pharma company’s ophthalmic sector and includes an optimally formulated non-controlled synthetic cannabinoid 2 receptor-selective agent for topical delivery to the eye.

Moreover, comprehensive preclinical studies have supported the Cannabinoid 2 receptor as an integral drug target for minimizing ocular pain and inflammation.

Speaking on the move, Dr. Guy Chamberland, CRO and CEO, Tetra BioPharma, said that the PPP003 series, which includes PPP003v, comes as an alluring prospect for the company as there is a massive unquenched medical need for severe inflammatory eye disorders. 

Moreover, these animal studies along with the veterinary program would offer crucial data, which could possibly be added as a chunk of the pre-clinical data essential for supporting the use of PPP003 in human clinical studies.

The company is extremely delighted to bag a validation from the U.S. FDA for its human ophthalmic research program and this marks as a significant milestone for Tetra, cites Dr. Chamberland.

Source Credit: https://finance.yahoo.com/news/tetra-bio-pharma-initiates-proof-130010929.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...